i to select an oral modified release MR formulation and dose of omecamtiv mecarbil for chronic twice daily BID dosing in subjects with HF and left ventricular systolic dysfunction and ii to characterize its pharmacokinetics PK over 20 weeks of treatment
Data and Resources
- A Double-blind Randomized Placebo-controlled Multicenter Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunctionjson
i to select an oral modified release MR formulation and dose of omecamtiv...
|Release Date|| |
|Public Access Level|| |